Ocular Therapeutix Inc Total Liabilities
Ocular Therapeutix Inc total liabilities. Based on the latest financial reports, Ocular Therapeutix Inc (OCUL) has total liabilities worth $151.28 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See OCUL defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Total Liabilities of Ocular Therapeutix Inc (2012–2025)
Total liabilities of Ocular Therapeutix Inc from 2012 to 2025. This chart illustrates how Ocular Therapeutix Inc's total liabilities have evolved over time, based on quarterly financial data. Check asset resilience ratio of Ocular Therapeutix Inc to evaluate the company's liquid asset resilience ratio.
Ocular Therapeutix Inc Competitors by Total Liabilities
The table below lists competitors of Ocular Therapeutix Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Tokai Carbon Korea Co. Ltd
KQ:064760
|
Korea | ₩53.47 Billion |
|
Ingenia Communities Group
AU:INA
|
Australia | AU$1.13 Billion |
|
Roshow Technology Co Ltd
SHE:002617
|
China | CN¥4.18 Billion |
|
Engineers India Limited
NSE:ENGINERSIN
|
India | Rs-31.46 Billion |
|
Mayinglong Pharmaceutical Group Co Ltd
SHG:600993
|
China | CN¥906.06 Million |
|
Altra Fastigheter AB (publ)
ST:ALTRA
|
Sweden | Skr26.64 Billion |
|
Hycroft Mining Holding Corporation
NASDAQ:HYMC
|
USA | $42.24 Million |
|
Charter Hall Retail REIT
AU:CQR
|
Australia | AU$1.40 Billion |
Liability Composition Analysis (2012–2025)
This chart breaks down Ocular Therapeutix Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see how large is Ocular Therapeutix Inc's balance sheet.
Liquidity & Leverage Metrics
Ocular Therapeutix Inc Total Liabilities Ratios Explained
Ocular Therapeutix Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 13.11 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.29 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.23 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Ocular Therapeutix Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Ocular Therapeutix Inc (2012–2025)
The table below shows the annual total liabilities of Ocular Therapeutix Inc from 2012 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $153.75 Million | +7.82% |
| 2024-12-31 | $142.59 Million | -11.40% |
| 2023-12-31 | $160.93 Million | +41.28% |
| 2022-12-31 | $113.91 Million | -2.55% |
| 2021-12-31 | $116.89 Million | -37.08% |
| 2020-12-31 | $185.77 Million | +125.53% |
| 2019-12-31 | $82.37 Million | +121.62% |
| 2018-12-31 | $37.17 Million | +26.92% |
| 2017-12-31 | $29.28 Million | +27.70% |
| 2016-12-31 | $22.93 Million | +10.68% |
| 2015-12-31 | $20.72 Million | +6.26% |
| 2014-12-31 | $19.50 Million | -75.20% |
| 2013-12-31 | $78.62 Million | +9.35% |
| 2012-12-31 | $71.90 Million | -- |
About Ocular Therapeutix Inc
Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as wel… Read more